A new ‘collective’ has been launched that will harness artificial intelligence (AI) technologies to improve outcomes for people fighting pancreatic cancer.
The Pancreatic Cancer Collective is a new initiative from Stand Up To Cancer (SU2C) and Lustgarten Foundation that will kick-off with $25 million to fast-track new research and solutions for those who need new treatments.
Research teams from both will work to build collaborations across industry and academia, tap into AI, and support the next wave of innovative therapies that can give renewed hope to people suffering from the disease.
“This is a watershed moment in the field of pancreatic cancer research. Through the Collective, these two organisations are uniquely positioned to engage and influence medical institutions, researchers and companies to achieve meaningful results faster,” said Nobel Laureate, Dr Phillip Sharp, chair of the Stand Up To Cancer Scientific Advisory Committee (SAC).
The platform will support the work of teams currently backed by the research organisations, as well as new scientists and institutions.
“The Collective will utilise the breadth and expertise of existing SU2C-Lustgarten Foundation Research Teams and researchers to support new investigators coming into the field and expand the capacity for additional research,” added Dr David Tuveson, Chief Scientist for the Lustgarten Foundation.